137 related articles for article (PubMed ID: 2168194)
1. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.
Katz EJ; Vick JS; Kling KM; Andrews PA; Howell SB
Eur J Cancer; 1990; 26(6):724-7. PubMed ID: 2168194
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Orengo G; Noviello E; Cimoli G; Pagnan G; Parodi S; Venturini M; Conte P; Schenone F; Conzi G; Russo P
Jpn J Cancer Res; 1992 Nov; 83(11):1132-6. PubMed ID: 1336489
[TBL] [Abstract][Full Text] [Related]
3. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones.
Frydman B; Marton LJ; Sun JS; Neder K; Witiak DT; Liu AA; Wang HM; Mao Y; Wu HY; Sanders MM; Liu LF
Cancer Res; 1997 Feb; 57(4):620-7. PubMed ID: 9044837
[TBL] [Abstract][Full Text] [Related]
4. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
5. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
7. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Minagawa Y; Kigawa J; Itamochi H; Terakawa N
Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells.
Gedik CM; Collins AR
Nucleic Acids Res; 1990 Feb; 18(4):1007-13. PubMed ID: 2156221
[TBL] [Abstract][Full Text] [Related]
9. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Kim JS; Amorino GP; Pyo H; Cao Q; Choy H
Radiother Oncol; 2002 Jan; 62(1):61-7. PubMed ID: 11830313
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
11. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Holden SA; Teicher BA; Robinson MF; Northey D; Rosowsky A
Cancer Chemother Pharmacol; 1995; 36(2):165-71. PubMed ID: 7767954
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
Musk SR; Steel GG
Br J Cancer; 1990 Sep; 62(3):364-7. PubMed ID: 2169851
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Stahl M; Kasimir-Bauer S; Harstrick A
Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase inhibitors induce irreversible fragmentation of replicated DNA in concanavalin A stimulated splenocytes.
Jaxel C; Taudou G; Portemer C; Mirambeau G; Panijel J; Duguet M
Biochemistry; 1988 Jan; 27(1):95-9. PubMed ID: 2831966
[TBL] [Abstract][Full Text] [Related]
16. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase inhibitors.
Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607
[No Abstract] [Full Text] [Related]
20. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]